Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Restructuring Reserve Liability by Quarter
Restructuring Reserve Liability — Total ending balance ($M) ($M)
Pfizer Restructuring Reserve Liability: $1,682M in Q2 2026, down 15.3% from a year earlier.
Latest, Q2 2026
1,682
Period ended Jun 28, 2026
Change on a year earlier
-15.3%
1,986 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
44
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Tracks Pfizer's multi-year Cost Realignment Program (~$4.9B cumulative costs through Q2 2026) and Manufacturing Optimization Program (~$1.1B cumulative costs through Q2 2026).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Reserve Liability — Total ending balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 1,682 | -15.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 1,588 | -33.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,910 | -9.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 1,836 | -13.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 1,986 | -17.2% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 2,399 | +46.5% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,120 | +6.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 2,132 | +264.4% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,399 | +236.0% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,638 | +118.4% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,988 | +65.1% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Oct 1, 2023 | 585 | -32.5% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 714 | -21.8% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 750 | -21.2% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,204 | +12.4% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Oct 2, 2022 | 867 | -23.6% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 913 | +53.2% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 952 | +32.8% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,071 | +34.2% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2021 | Oct 3, 2021 | 1,135 | +34.0% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 596 | -37.3% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 717 | +0.4% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 798 | -2.2% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2020 | Sep 27, 2020 | 847 | +15.4% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 951 | +19.3% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 714 | -34.7% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 816 | -29.7% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2019 | Sep 29, 2019 | 734 | -7.8% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 797 | -9.1% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,093 | +9.8% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,161 | +5.1% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 796 | -32.7% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 877 | -33.5% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 995 | -31.3% | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,105 | -30.2% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,182 | -7.3% | SEC Filing ↗ |
| Q2 2017 | Jul 2, 2017 | 1,319 | +29.6% | SEC Filing ↗ |
| Q1 2017 | Apr 2, 2017 | 1,449 | +43.3% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 1,583 | +36.8% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2016 | Oct 2, 2016 | 1,275 | +9.4% | SEC Filing ↗ |
| Q2 2016 | Jul 3, 2016 | 1,018 | +1.0% | SEC Filing ↗ |
| Q1 2016 | Apr 3, 2016 | 1,011 | -3.3% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 1,157 | – | Form 10-K (filed 2018-02-22) ↗ |
| Q3 2015 | Sep 27, 2015 | 1,165 | – | SEC Filing ↗ |
| Q2 2015 | Jun 28, 2015 | 1,008 | – | SEC Filing ↗ |
| Q1 2015 | Mar 29, 2015 | 1,046 | – | SEC Filing ↗ |
Breakdown
What makes up restructuring Reserve Liability
- Restructuring reserve — Current liability ($M)972 · Q2 2026
- Restructuring reserve — Noncurrent liability ($M)710 · Q2 2026
- Restructuring reserve — Employee termination / severance costs ($M)1,575 · Q2 2026
- Restructuring reserve — Exit & other restructuring activities ($M)107 · Q2 2026
- Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M)4,900 · Q2 2026
- Cost Realignment Program — Cumulative costs attributable to Biopharma ($M)3,800 · Q2 2026
- Cost Realignment Program — Total expected program one-time costs ($M)4,700 · Q2 2026
- Manufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M)1,100 · Q2 2026
- Manufacturing Optimization Program — Total expected Phase 1 costs ($M)1,400 · Q2 2026
- Restructuring charges recognized in period — Total ($M)419 · Q2 2026
- Restructuring charges — Employee termination costs ($M)354 · Q2 2026
- Restructuring-related asset impairments ($M)54 · Q2 2026
- Restructuring charges — Exit & other costs ($M)11 · Q2 2026
- Restructuring reserve utilization / cash payments — Total ($M)324 · Q2 2026
- Restructuring reserve utilization — Severance payments ($M)247 · Q2 2026
- Acquisition integration & implementation costs ($M)653 · Q2 2026
Cite this data
StockData. (2026). Pfizer Restructuring Reserve Liability ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-res-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.